|
Volumn 35, Issue SUPPL. 1, 2007, Pages
|
Concomitant effects of a rapid and short acting insulin secretagogue mitiglinide in type 2 diabetes patients with inadequate control with α-glucosidase inhibitor monotherapy - Phase III open label study
a b c d e f g h i j j |
Author keywords
GI; Combination therapy; HbA1C; Mitiglinide; Postprandial blood glucose
|
Indexed keywords
ACARBOSE;
ALPHA GLUCOSIDASE INHIBITOR;
DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE;
GLUCOSE;
HEMOGLOBIN A1C;
INSULIN;
MITIGLINIDE;
SHORT ACTING DRUG;
VOGLIBOSE;
ARTICLE;
BLOOD GLUCOSE MONITORING;
CLINICAL ARTICLE;
CLINICAL FEATURE;
CLINICAL STUDY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIET THERAPY;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
INCIDENCE;
LABORATORY TEST;
MONOTHERAPY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PHASE 3 CLINICAL TRIAL;
TREATMENT DURATION;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
VITAL SIGN;
|
EID: 34250877814
PISSN: 03863603
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (1)
|
References (5)
|